Altium Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-40,000
| Closed | -$2.02M | – | 76 |
|
|
2024
Q3 | $2.02M | Sell |
40,000
-75,000
| -65% | -$3.78M | 0.59% | 42 |
|
|
2024
Q2 | $5.06M | Buy |
+115,000
| New | +$5.06M | 2.06% | 19 |
|
|
2023
Q4 | – | Sell |
-88,000
| Closed | -$5.02M | – | 77 |
|
|
2023
Q3 | $5.02M | Hold |
88,000
| – | – | 2.62% | 14 |
|
|
2023
Q2 | $4.49M | Buy |
+88,000
| New | +$4.49M | 3.4% | 10 |
|
|
2022
Q1 | – | Sell |
-250,000
| Closed | -$2.47M | – | 143 |
|
|
2021
Q4 | $2.47M | Hold |
250,000
| – | – | 0.68% | 57 |
|
|
2021
Q3 | $2.49M | Hold |
250,000
| – | – | 0.65% | 62 |
|
|
2021
Q2 | $2.59M | Hold |
250,000
| – | – | 0.6% | 67 |
|
|
2021
Q1 | $2.55M | Hold |
250,000
| – | – | 0.71% | 59 |
|
|
2020
Q4 | $2.84M | Buy |
+250,000
| New | +$2.84M | 1.06% | 41 |
|